Share Twitter LinkedIn Facebook Email Deepu Madduri, MD Assistant Professor, Medicine, Hematology and Medical Oncology, @MountSinaiNYC explains how JNJ-4528 differs from other CAR-T products.
Teclistamab FDA Approval Biweekly Dosing Multiple Myeloma [3 KOL Interviews] Multiple Myeloma 13 Mins Read